GlassScriptPhysician profile
Jasmine Nazari
NPI 1396311205
$3,928.96
in general payments reported to CMS, 2019-2025
19 companies · $2,271 in 2025
The $2,271 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $389 · 2023: $561 · 2024: $707 · 2025: $2,271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,364 · Education: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,363.66 |
| Education | $176.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $736.16 | 2022-2025 | Dupixent |
| Genzyme Corporation | $636.89 | 2022-2025 | |
| Incyte Corporation | $574.44 | 2022-2025 | Opzelura, Opzelura |
| Galderma Laboratories, L.P. | $481.44 | 2025 | Nemluvio |
| Abbvie INC. | $349.49 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $216.72 | 2023-2025 | |
| Ucb, INC. | $157.10 | 2025 | Bimzelx |
| Lilly USA, LLC | $131.24 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $112.87 | 2024 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Allergan, INC. | $99.22 | 2022 | |
| Janssen Biotech, INC. | $91.84 | 2025 | Simponi, Stelara, Tremfya |
| Leo Pharma INC. | $52.46 | 2025 | Anzupgo, Adbry |
| Revance Therapeutics, INC. | $44.21 | 2025 | Daxxify |
| Organon LLC | $35.43 | 2025 | Vtama |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $33.99 | 2022 | |
| Sun Pharmaceutical Industries INC. | $32.71 | 2022-2025 | |
| Botanix Sb INC | $26.14 | 2025 | Sofdra |
| Arcutis Biotherapeutics, INC. | $16.62 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmine Nazari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.